Open AccessEconomic Study on the Impact of Side Effects in Patients Taking Oxycodone Controlled-Release for Noncancer Pain
Author(s) -
Kathryn Anastassopoulos,
Wing Chow,
Crisanta I Tapia,
Rebecca Baik,
Stacey J. Ackerman,
David M. Biondi,
Myoung Soo Kim
Publication year - 2012
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2012.18.8.615
Subject(s) - medicine , oxycodone , neuropathic pain , reimbursement , medical prescription , physical therapy , opioid , chronic pain , anesthesia , health care , receptor , economics , pharmacology , economic growth
Chronic pain is a prevalent condition in the United States. Musculoskeletal pain, including joint and back pain, is the most common type of chronic pain, and many patients with back pain have a neuropathic component. Pain has direct economic consequences. While oxycodone controlled-release (CR) is one of the most widely used oral long-acting opioids for pain, including pain with a neuropathic component, it is often associated with bothersome side effects, resulting in additional medical resource use (MRU) and costs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom